CereVasc Completes $85 Million Series C Financing to Advance eShunt System for Normal Pressure Hydrocephalus
CereVasc has completed an over-subscribed $85 million Series C financing led by Piper Sandler Merchant Banking, with participation from Johnson & Johnson Innovation and Medtronic. The funds will support the STRIDE pivotal trial of its eShunt® System for Normal Pressure Hydrocephalus (NPH), regulatory submissions to the FDA, operational scale-up, and US commercialization preparations.
Topics: Biotech Financing FDA Regulatory Pathway Medical Device